Global Antiemetic Drug Market 2023-2027

Description

List of Tables

The antiemetic drug market is forecasted to grow by USD 1,632.81 mn during 2022-2027, accelerating at a CAGR of 6.47% during the forecast period. The report on the antiemetic drug market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising geriatric population globally, growing prevalence of nausea and vomiting, and increasing healthcare expenditure.

Technavio's antiemetic drug market is segmented as below:

By Application

Chemotherapy
Surgery
Gastroenteritis
Others

By Drug Class

5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist
Dopamine antagonist
Neurokinin-1 (NK 1) receptor antagonist
Cannabinoid receptor antagonist
Others

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the integration of digital health solutions in antiemetic drug management as one of the prime reasons driving the antiemetic drug market growth during the next few years. Also, growing number of recent developments related to antiemetic drugs and rising demand for antiemetic drugs in emerging economies will lead to sizable demand in the market.

The report on the antiemetic drug market covers the following areas:

Antiemetic drug market sizing
Antiemetic drug market forecast
Antiemetic drug market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading antiemetic drug market vendors that include Algen Healthcare Ltd., Boehringer Ingelheim International GmbH, Bristol Laboratories Ltd., Cadila Pharmaceuticals Ltd., Cipla Ltd., Eagle Pharmaceuticals Inc., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Helsinn Healthcare SA, Heron Therapeutics Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., RedHill Biopharma Ltd., Sanofi, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.. Also, the antiemetic drug market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR75902

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 06: Executive Summary - Chart on Market Segmentation by Application
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global antiemetic drug market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on global antiemetic drug market 2017 - 2021 ($ million)
4.2 Drug Class Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Drug Class Segment 2017 - 2021 ($ million)
4.3 Application Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Application Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Drug Class

6.1 Market segments
Exhibit 30: Chart on Drug Class - Market share 2022-2027 (%)
Exhibit 31: Data Table on Drug Class - Market share 2022-2027 (%)
6.2 Comparison by Drug Class
Exhibit 32: Chart on Comparison by Drug Class
Exhibit 33: Data Table on Comparison by Drug Class
6.3 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist - Market size and forecast 2022-2027
Exhibit 34: Chart on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist - Year-over-year growth 2022-2027 (%)
6.4 Dopamine antagonist - Market size and forecast 2022-2027
Exhibit 38: Chart on Dopamine antagonist - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on Dopamine antagonist - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on Dopamine antagonist - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Dopamine antagonist - Year-over-year growth 2022-2027 (%)
6.5 Neurokinin-1 (NK 1) receptor antagonist - Market size and forecast 2022-2027
Exhibit 42: Chart on Neurokinin-1 (NK 1) receptor antagonist - Market size and forecast 2022-2027 ($ million)
Exhibit 43: Data Table on Neurokinin-1 (NK 1) receptor antagonist - Market size and forecast 2022-2027 ($ million)
Exhibit 44: Chart on Neurokinin-1 (NK 1) receptor antagonist - Year-over-year growth 2022-2027 (%)
Exhibit 45: Data Table on Neurokinin-1 (NK 1) receptor antagonist - Year-over-year growth 2022-2027 (%)
6.6 Cannabinoid receptor antagonist - Market size and forecast 2022-2027
Exhibit 46: Chart on Cannabinoid receptor antagonist - Market size and forecast 2022-2027 ($ million)
Exhibit 47: Data Table on Cannabinoid receptor antagonist - Market size and forecast 2022-2027 ($ million)
Exhibit 48: Chart on Cannabinoid receptor antagonist - Year-over-year growth 2022-2027 (%)
Exhibit 49: Data Table on Cannabinoid receptor antagonist - Year-over-year growth 2022-2027 (%)
6.7 Others - Market size and forecast 2022-2027
Exhibit 50: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 51: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 52: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibit 53: Data Table on Others - Year-over-year growth 2022-2027 (%)
6.8 Market opportunity by Drug Class
Exhibit 54: Market opportunity by Drug Class ($ million)
Exhibit 55: Data Table on Market opportunity by Drug Class ($ million)

7 Market Segmentation by Application

7.1 Market segments
Exhibit 56: Chart on Application - Market share 2022-2027 (%)
Exhibit 57: Data Table on Application - Market share 2022-2027 (%)
7.2 Comparison by Application
Exhibit 58: Chart on Comparison by Application
Exhibit 59: Data Table on Comparison by Application
7.3 Chemotherapy - Market size and forecast 2022-2027
Exhibit 60: Chart on Chemotherapy - Market size and forecast 2022-2027 ($ million)
Exhibit 61: Data Table on Chemotherapy - Market size and forecast 2022-2027 ($ million)
Exhibit 62: Chart on Chemotherapy - Year-over-year growth 2022-2027 (%)
Exhibit 63: Data Table on Chemotherapy - Year-over-year growth 2022-2027 (%)
7.4 Surgery - Market size and forecast 2022-2027
Exhibit 64: Chart on Surgery - Market size and forecast 2022-2027 ($ million)
Exhibit 65: Data Table on Surgery - Market size and forecast 2022-2027 ($ million)
Exhibit 66: Chart on Surgery - Year-over-year growth 2022-2027 (%)
Exhibit 67: Data Table on Surgery - Year-over-year growth 2022-2027 (%)
7.5 Gastroenteritis - Market size and forecast 2022-2027
Exhibit 68: Chart on Gastroenteritis - Market size and forecast 2022-2027 ($ million)
Exhibit 69: Data Table on Gastroenteritis - Market size and forecast 2022-2027 ($ million)
Exhibit 70: Chart on Gastroenteritis - Year-over-year growth 2022-2027 (%)
Exhibit 71: Data Table on Gastroenteritis - Year-over-year growth 2022-2027 (%)
7.6 Others - Market size and forecast 2022-2027
Exhibit 72: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 73: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 74: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibit 75: Data Table on Others - Year-over-year growth 2022-2027 (%)
7.7 Market opportunity by Application
Exhibit 76: Market opportunity by Application ($ million)
Exhibit 77: Data Table on Market opportunity by Application ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 78: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 79: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibit 80: Data Table on Market share By Geographical Landscape 2022-2027 (%)
9.2 Geographic comparison
Exhibit 81: Chart on Geographic comparison
Exhibit 82: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 83: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 84: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 85: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 86: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 87: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 88: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 89: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 90: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 91: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 92: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 93: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 94: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 95: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 96: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 97: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 98: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 99: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 100: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 101: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 102: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 China - Market size and forecast 2022-2027
Exhibit 103: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibit 104: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibit 105: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 106: Data Table on China - Year-over-year growth 2022-2027 (%)
9.9 Germany - Market size and forecast 2022-2027
Exhibit 107: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 108: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 109: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 110: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.10 Japan - Market size and forecast 2022-2027
Exhibit 111: Chart on Japan - Market size and forecast 2022-2027 ($ million)
Exhibit 112: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
Exhibit 113: Chart on Japan - Year-over-year growth 2022-2027 (%)
Exhibit 114: Data Table on Japan - Year-over-year growth 2022-2027 (%)
9.11 UK - Market size and forecast 2022-2027
Exhibit 115: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 116: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 117: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 118: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 119: Market opportunity By Geographical Landscape ($ million)
Exhibit 120: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 121: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 122: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 123: Overview on factors of disruption
11.4 Industry risks
Exhibit 124: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 125: Vendors covered
12.2 Market positioning of vendors
Exhibit 126: Matrix on vendor position and classification
12.3 Boehringer Ingelheim International GmbH
Exhibit 127: Boehringer Ingelheim International GmbH - Overview
Exhibit 128: Boehringer Ingelheim International GmbH - Business segments
Exhibit 129: Boehringer Ingelheim International GmbH - Key news
Exhibit 130: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 131: Boehringer Ingelheim International GmbH - Segment focus
12.4 Cadila Pharmaceuticals Ltd.
Exhibit 132: Cadila Pharmaceuticals Ltd. - Overview
Exhibit 133: Cadila Pharmaceuticals Ltd. - Product / Service
Exhibit 134: Cadila Pharmaceuticals Ltd. - Key offerings
12.5 Cipla Ltd.
Exhibit 135: Cipla Ltd. - Overview
Exhibit 136: Cipla Ltd. - Business segments
Exhibit 137: Cipla Ltd. - Key news
Exhibit 138: Cipla Ltd. - Key offerings
Exhibit 139: Cipla Ltd. - Segment focus
12.6 Fresenius SE and Co. KGaA
Exhibit 140: Fresenius SE and Co. KGaA - Overview
Exhibit 141: Fresenius SE and Co. KGaA - Business segments
Exhibit 142: Fresenius SE and Co. KGaA - Key news
Exhibit 143: Fresenius SE and Co. KGaA - Key offerings
Exhibit 144: Fresenius SE and Co. KGaA - Segment focus
12.7 GlaxoSmithKline Plc
Exhibit 145: GlaxoSmithKline Plc - Overview
Exhibit 146: GlaxoSmithKline Plc - Business segments
Exhibit 147: GlaxoSmithKline Plc - Key news
Exhibit 148: GlaxoSmithKline Plc - Key offerings
Exhibit 149: GlaxoSmithKline Plc - Segment focus
12.8 Helsinn Healthcare SA
Exhibit 150: Helsinn Healthcare SA - Overview
Exhibit 151: Helsinn Healthcare SA - Product / Service
Exhibit 152: Helsinn Healthcare SA - Key offerings
12.9 Lupin Ltd.
Exhibit 153: Lupin Ltd. - Overview
Exhibit 154: Lupin Ltd. - Product / Service
Exhibit 155: Lupin Ltd. - Key news
Exhibit 156: Lupin Ltd. - Key offerings
12.10 Merck and Co. Inc.
Exhibit 157: Merck and Co. Inc. - Overview
Exhibit 158: Merck and Co. Inc. - Business segments
Exhibit 159: Merck and Co. Inc. - Key news
Exhibit 160: Merck and Co. Inc. - Key offerings
Exhibit 161: Merck and Co. Inc. - Segment focus
12.11 Novartis AG
Exhibit 162: Novartis AG - Overview
Exhibit 163: Novartis AG - Business segments
Exhibit 164: Novartis AG - Key offerings
Exhibit 165: Novartis AG - Segment focus
12.12 Otsuka Holdings Co. Ltd.
Exhibit 166: Otsuka Holdings Co. Ltd. - Overview
Exhibit 167: Otsuka Holdings Co. Ltd. - Business segments
Exhibit 168: Otsuka Holdings Co. Ltd. - Key offerings
Exhibit 169: Otsuka Holdings Co. Ltd. - Segment focus
12.13 Pfizer Inc.
Exhibit 170: Pfizer Inc. - Overview
Exhibit 171: Pfizer Inc. - Product / Service
Exhibit 172: Pfizer Inc. - Key news
Exhibit 173: Pfizer Inc. - Key offerings
12.14 Sanofi
Exhibit 174: Sanofi - Overview
Exhibit 175: Sanofi - Business segments
Exhibit 176: Sanofi - Key news
Exhibit 177: Sanofi - Key offerings
Exhibit 178: Sanofi - Segment focus
12.15 Takeda Pharmaceutical Co. Ltd.
Exhibit 179: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibit 180: Takeda Pharmaceutical Co. Ltd. - Product / Service
Exhibit 181: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibit 182: Takeda Pharmaceutical Co. Ltd. - Key offerings
12.16 Teva Pharmaceutical Industries Ltd.
Exhibit 183: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 184: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 185: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 186: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 187: Teva Pharmaceutical Industries Ltd. - Segment focus
12.17 Viatris Inc.
Exhibit 188: Viatris Inc. - Overview
Exhibit 189: Viatris Inc. - Business segments
Exhibit 190: Viatris Inc. - Key news
Exhibit 191: Viatris Inc. - Key offerings
Exhibit 192: Viatris Inc. - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 193: Inclusions checklist
Exhibit 194: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 195: Currency conversion rates for US$
13.4 Research methodology
Exhibit 196: Research methodology
Exhibit 197: Validation techniques employed for market sizing
Exhibit 198: Information sources
13.5 List of abbreviations
Exhibit 199: List of abbreviations